Viropro, Immuno Japan sign license for therapeutic proteins

By Elaine Rigoli

Tampa, Fla., April 11 - Viropro, Inc. has signed an exclusive licensing agreement with Immuno Japan, Inc., giving Viropro exclusive worldwide marketing rights (except for Japan) for patented new therapeutic proteins.

Viropro will pay $1,050,000 in the form of 3,500,000 shares for the license, according to a news release.

This agreement is meant to preserve the company's liquidity, thereby ensuring the business development outlined in its strategic objectives, the release said.

Immuno Japan is a Tokyo-based pharmaceutical company.

Based in Montreal, Quebec, Viropro develops and sells therapeutic proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.